Success Metrics

Clinical Success Rate
60.0%

Based on 6 completed trials

Completion Rate
60%(6/10)
Active Trials
1(7%)
Results Posted
117%(7 trials)
Terminated
4(29%)

Phase Distribution

Ph phase_1
2
14%
Ph phase_4
2
14%
Ph phase_2
7
50%
Ph phase_3
3
21%

Phase Distribution

2

Early Stage

7

Mid Stage

5

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
2(14.3%)
Phase 2Efficacy & side effects
7(50.0%)
Phase 3Large-scale testing
3(21.4%)
Phase 4Post-market surveillance
2(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

6 of 12 finished

Non-Completion Rate

50.0%

6 ended early

Currently Active

1

trials recruiting

Total Trials

14

all time

Status Distribution
Active(1)
Completed(6)
Terminated(6)
Other(1)

Detailed Status

Completed6
Terminated4
Withdrawn2
Recruiting1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
1
Success Rate
60.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (14.3%)
Phase 27 (50.0%)
Phase 33 (21.4%)
Phase 42 (14.3%)

Trials by Status

completed643%
withdrawn214%
recruiting17%
suspended17%
terminated429%

Recent Activity

1 active trials
Showing 5 of 14
completedphase_2

Vigabatrin and Insulin Sensitivity

NCT04321395
recruitingphase_2

Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants

NCT04987463
terminatedphase_3

A Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms

NCT03421496
suspendedphase_3

A Novel Approach to Infantile Spasms

NCT03347526
withdrawnphase_3

Prednisolone Versus Vigabatrin in the First-line Treatment of Infantile Spasms

NCT02299115
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT04321395Phase 2

Vigabatrin and Insulin Sensitivity

Completed
NCT04987463Phase 2

Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants

Recruiting
NCT03421496Phase 3

A Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms

Terminated
NCT03347526Phase 3

A Novel Approach to Infantile Spasms

Suspended
NCT02299115Phase 3

Prednisolone Versus Vigabatrin in the First-line Treatment of Infantile Spasms

Withdrawn
NCT01335867Phase 2

Vigabatrin for Cocaine and Alcohol Dependence

Terminated
NCT01585207Phase 1

Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder

Completed
NCT01266291Phase 4

Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) Patients

Terminated
NCT00626834Phase 1

Vigabatrin Ph 1 Cocaine Interaction Study

Completed
NCT00373581Phase 2

Effects of Vigabatrin on Cocaine Self-Administration

Terminated
NCT01281202Phase 2

Vigabatrin for the Treatment of Cocaine Dependency

Completed
NCT00611130Phase 2

Vigabatrin for Treatment of Cocaine Dependence

Completed
NCT01413711Phase 4

An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile Spasms

Withdrawn
NCT00527683Phase 2

Double Blind Study of Vigabatrin for the Treatment of Cocaine Dependence

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14